Shaw and Partners appointed as Lead Manager to the equity capital raising by Recce Pharmaceuticals News08 Oct 2019

Shaw and Partners has been appointed as Lead Manager to an equity capital raising by Recce Pharmaceuticals Limited (RCE).


RCE is undertaking a placement of approx. 15.5 million new securities to raise a minimum of $4 million. The company is reserving the right to accept oversubscriptions.


The offer price of $0.26 per security represents a 17.5% discount to last close of $0.315 as at 7 October 2019 and a 20.0% discount to a 15 day VWAP of $0.325 as at 7 October 2019.


The offer is available to Australian resident Sophisticated and Professional Investor clients only.


For more information please contact your Shaw and Partners Adviser.


About Recce Pharmaceuticals

Recce Pharmaceuticals Ltd is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad spectrum activity designed to address the urgent global health problem of antibiotic resistant superbugs. Wholly owned RECCE® antibiotics are unique; potency does not diminish even with repeated use, the common failure associated with existing antibiotics and their resulting emergence of resistant superbugs. Patented lead candidate RECCE® 327 has been developed for the treatment of blood infections and bacterial sepsis, affecting over 30 million people worldwide a year, growing at 8-13% per annum.


There are currently no drug therapies specifically for the treatment of severe sepsis and by far the most expensive condition treated in US hospitals. The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post-approval. Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of RECCE® technologies targeting synergistic, unmet medical needs.

Related Articles
News24 Feb 2020 Shaw and Partners Race Team Member Danielle McKenzie wins the 2020 Investec Bridge to Beach
On Sunday 23 February, the 2019/20 Australian Ocean Racing Series (AORS) concluded the season in Sydney with the Investec Bridge to Beach race. For the fourth year running, Shaw an... Read More
News18 Feb 2020 EFG Global Sport Ambassador Tiffany Chan visits the Shaw and Partners office in Adelaide.
Shaw and Partners was delighted to have professional golfer Tiffany Chan visit our Adelaide office last Friday.    Tiffany is Global Sport Ambassador of our parent company EFG In... Read More
News17 Feb 2020 Shaw and Partners appointed Co-Manager to the NAB Capital Notes 4 offer
National Australia Bank Limited (NAB) today announced its intention to raise $750 million through the offer of NAB Capital Notes 4, with the ability to raise more or less.   Shaw... Read More
News17 Feb 2020 Matt Bevilacqua and Brielle Cooper win the second edition of the Shaw and Partners Shannon Eckstein Ironman Classic
Over the weekend, the second edition of the Shaw and Partners Shannon Eckstein Ironman Classic took place at BMD Northcliffe Surf Life Saving Club on the Gold Coast, showcasing one... Read More
A - Z  % Change  
{{data.Symbol}} {{data.CompanyName}} {{data.Close}} {{data.AsAt | date :'shortTime'}} {{data.Movement | number : 2}} {{data.MovementPercent | number: 2}}%